These findings identify FTO as a key epitranscriptomic regulator of glutamine metabolic reprogramming in ccRCC, suggesting that inhibiting FTO could be an effective therapeutic strategy for targeting glutamine reprogramming in ccRCC. This evidence concerns the gene FTO and nonpapillary renal cell carcinoma.